A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR JAPAN? SIMULATING THE POTENTIAL IMPACT ON THE PRICE OF SIMEPREVIR.
Mahlich, Jörg; Kamae, Isao; Rossi, Bruno.
Int J Technol Assess Health Care
; 33(1): 121-127, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28560939
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?